

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT	DISEASE Peritoneum serous carcinoma	PHYSICIAN	ORDERING PHYSICIAN Yeh, Yi-Chen	SPECIMEN	SPECIMEN SITE Omentum
	NAME Tsai, Shu Chen		MEDICAL FACILITY Taipei Veterans General Hospital		SPECIMEN ID N2218086
	DATE OF BIRTH 29 January 1970		ADDITIONAL RECIPIENT None		SPECIMEN TYPE Slide Deck
	SEX Female		MEDICAL FACILITY ID 205872		DATE OF COLLECTION 05 September 2022
	MEDICAL RECORD # 48953851		PATHOLOGIST Not Provided		SPECIMEN RECEIVED 17 October 2022

Biomarker Findings

Homologous Recombination status - HRD Not Detected

Loss of Heterozygosity score - 8.8%

Microsatellite status - MS-Stable

Tumor Mutational Burden - 2 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

TSC1 A186fs*26

TP53 G244D

2 Disease relevant genes with no reportable alterations: **BRCA1**, **BRCA2**

Report Highlights

- Targeted therapies with potential clinical benefit approved in another tumor type: Nab-sirolimus (p. [6](#))
- Evidence-matched clinical trial options based on this patient's genomic findings: (p. [7](#))

BIOMARKER FINDINGS

Homologous Recombination status - HRD Not Detected

Loss of Heterozygosity score - 8.8%

Microsatellite status - MS-Stable

Tumor Mutational Burden - 2 Muts/Mb

GENOMIC FINDINGS

TSC1 - A186fs*26

9 Trials see p. [8](#)

TP53 - G244D

2 Trials see p. [7](#)

THERAPY AND CLINICAL TRIAL IMPLICATIONS

HRD Not Detected defined as absence of deleterious **BRCA1/2** alteration and LOH score < 16% or Cannot Be Determined (Coleman et al., 2017; 28916367).

No therapies or clinical trials. See Biomarker Findings section

No therapies or clinical trials. See Biomarker Findings section

No therapies or clinical trials. See Biomarker Findings section

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
none	Nab-sirolimus
none	none

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

BIOMARKER FINDINGS

BIOMARKER

Loss of Heterozygosity score

RESULT
8.8%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors^{1,2}. In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, rucaparib elicited significantly longer median PFS (7.2 vs. 5.0 months, HR=0.51) and improved ORR (33.3% vs. 9.6%, p=0.0003) for patients with LOH score $\geq 16\%$ ². In the maintenance setting in platinum-sensitive, BRCA1/2 wild-type patients, rucaparib was superior to placebo in both the LOH score $\geq 16\%$ (median PFS, 9.7 vs. 5.4 months; HR=0.44) and LOH score $< 16\%$ (median PFS, 6.7 vs. 5.4 months; HR=0.58) cohorts¹. Similar results have been reported for maintenance treatment with niraparib in ovarian cancer³ when using a different measure

of HRD that includes genomic LOH⁴⁻⁵. Increased LOH has also been associated with improved sensitivity to platinum-containing chemotherapy regimens in patients with ovarian or breast cancer⁶⁻⁸.

FREQUENCY & PROGNOSIS

In a study of more than 4,000 ovarian, Fallopian tube, or peritoneal cancer samples, genomic LOH score $\geq 16\%$ was identified in 24.2% of BRCA1/2 wild-type cases, deleterious BRCA1/2 mutation was identified in an additional 17.2% of cases, and the remaining 58.7% of cases had LOH score $< 16\%$ and were BRCA1/2 wild-type⁹. Among the histological subtypes, LOH score $\geq 16\%$ or BRCA1/2 mutation was reported in 42.4% of serous carcinomas, 37.6% of endometrioid carcinomas, 23.5% of carcinosarcomas, 20.6% of neuroendocrine carcinomas, 13.6% of clear cell carcinomas, and 8.1% of mucinous carcinomas; in BRCA1/2 wild-type samples, the median LOH score was significantly higher in serous as compared with non-serous cases⁹. In ovarian carcinoma, the median LOH score is significantly higher for BRCA1/2-mutated cases than BRCA1/2 wild-type cases (22.2% vs. 9.8%)⁹, and mutation or methylation of BRCA1, BRCA2, or RAD51C has been reported to be enriched in cases with

increased genomic LOH^{6,10}. One study reported no association between LOH and either tumor stage or grade in ovarian serous carcinoma¹¹. In patients with high-grade serous ovarian carcinoma, the frequency of LOH has been reported to increase significantly with age¹².

FINDING SUMMARY

The loss of heterozygosity (LOH) score is a profile of the percentage of the tumor genome that is under focal loss of one allele²; focal LOH events accumulate as genomic "scars" as a result of incorrect DNA double-strand break repair when the homologous recombination pathway is deficient (HRD)^{6,10,13-14}. HRD and consequent genomic LOH occur as a result of genetic or epigenetic inactivation of one or more of the homologous recombination pathway proteins, including BRCA1, BRCA2, RAD51C, ATM, PALB2, and BRIP1¹³⁻¹⁶. This sample harbors a genomic LOH score below levels that have been associated with improved rates of clinical benefit from treatment with the PARP inhibitor rucaparib in patients with platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma². However, patients with lower genomic LOH have also responded to rucaparib, and this type of LOH score does not preclude benefit from PARP inhibitors^{1,2}.

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors¹⁷⁻¹⁹, including approved therapies nivolumab and pembrolizumab²⁰. In a retrospective analysis of 361 patients with solid tumors treated

with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)²¹.

FREQUENCY & PROGNOSIS

MSI-high (MSI-H) has been reported in 1.6-19.7% of ovarian cancer samples²²⁻²³, including 3.8% (1/26) of ovarian endometrioid adenocarcinomas²⁴, and 10.0% (3/30) of ovarian clear cell carcinomas (CCOCs)²⁵. No association of MSI-H with stage or survival was found in patients with ovarian cancer^{22,26}.

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of

genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor²⁷. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2²⁷⁻²⁹. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers³⁰⁻³². MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins^{27,29,31-32}.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

BIOMARKER FINDINGS

BIOMARKER

Tumor Mutational Burden

RESULT

2 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1³³⁻³⁵, anti-PD-1 therapies³³⁻³⁶, and combination nivolumab and ipilimumab³⁷⁻⁴². In multiple pan-tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors^{33-36,43-47}. In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥ 10 Muts/Mb (as measured by this assay) compared with those with TMB < 10 Muts/Mb in a large cohort that included multiple tumor types⁴³; similar findings were observed in the KEYNOTE 028 and 012 trials³⁶. At the same TMB cutpoint, retrospective analysis of

patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores < 10 Muts/Mb (HR=0.68)⁴⁷. For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples⁴⁸. However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan-solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and < 16 Muts/Mb⁴⁶. Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as ≥ 16 -20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy compared with patients with higher TMB treated with chemotherapy⁴⁹ or those with lower TMB treated with PD-1 or PD-L1-targeting agents³⁴.

FREQUENCY & PROGNOSIS

Ovarian carcinomas, including peritoneal and Fallopian tube carcinomas, harbor a median TMB of 2.7-3.6 mutations per megabase (Muts/Mb) depending upon subtype, and up to 2.1% of cases

have high TMB (> 20 Muts/Mb)⁵⁰. In a study of high grade serous ovarian cancer, homologous recombination (HR)-deficient tumors, which comprised ~50% of all samples, harbored a higher neoantigen load compared to HR-proficient tumors; higher neoantigen load was associated with longer OS but not disease free survival⁵¹.

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma⁵²⁻⁵³ and cigarette smoke in lung cancer⁵⁴⁻⁵⁵, treatment with temozolomide-based chemotherapy in glioma⁵⁶⁻⁵⁷, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes⁵⁸⁻⁶², and microsatellite instability (MSI)^{58,61-62}. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types^{34-35,43}.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

GENOMIC FINDINGS

GENE

TSC1

ALTERATION

A186fs*26

TRANSCRIPT ID

NM_000368.4

CODING SEQUENCE EFFECT

557_573delCACTCTTTCATCGCCTT

VARIANT CHROMOSOMAL POSITION

chr9:135797295-135797312

VARIANT ALLELE FREQUENCY (% VAF)

47.2%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Loss or inactivation of TSC1 can activate mTOR signaling⁶³⁻⁶⁴; however, response rates for patients with TSC1-mutated solid tumors treated with MTOR inhibitors such as everolimus and temsirolimus have been low⁶⁵⁻⁶⁷. In the prospective NCI-MATCH study, the ORR for patients with various TSC1-mutated solid tumors treated with

everolimus was 7.7% (1/13); the single response was reported for a patient with urothelial cancer⁶⁵. In TSC1-mutated renal cell carcinoma (RCC), although responses to MTOR inhibitors have been described in multiple case series and reports⁶⁸⁻⁷², retrospective analysis of a broader cohort showed no responses in TSC1-mutated RCC (0/7)⁶⁶. Retrospective analyses of the RECORD-3, GRANITE-1, and EVOLVE-1 studies of everolimus to treat patients with RCC, gastric cancer, or hepatocellular carcinoma, respectively, showed no significant association between alterations in MTOR, TSC1, or TSC2 and median PFS⁶⁷. PRs have been reported for patients with TSC1-altered perivascular epithelioid cell tumors⁷³⁻⁷⁴ and epithelial ovarian carcinoma⁷⁵ treated with nab-sirolimus.

FREQUENCY & PROGNOSIS

TSC1 deletion or mutation has been reported in 1% and 0.6% of ovarian serous carcinomas, respectively¹⁵. Loss of heterozygosity of chromosome 9q, a region that includes TSC1 and TSC2, has been reported in 54-79% of ovarian carcinoma samples, and associated with late stage

and higher grade tumors⁷⁶⁻⁷⁹. Published data investigating the prognostic implications of TSC1 alterations in ovarian carcinoma are limited (PubMed, Sep 2022).

FINDING SUMMARY

TSC1 encodes the protein Hamartin, which interacts with Tuberin, the gene product of TSC2, to inhibit and regulate mTOR activity^{63,80}. Alterations such as seen here may disrupt TSC1 function or expression⁸¹⁻⁸³.

POTENTIAL GERMLINE IMPLICATIONS

Inactivating germline mutations in TSC1 are associated with the autosomal dominant disorder tuberous sclerosis complex, which results in the development of hamartomas in multiple organ systems and an increased risk of developing renal cell carcinoma⁸⁴⁻⁸⁵. TSC1 mutations account for approximately 10 to 30% of reported sporadic cases⁸⁶. Prevalence for this disorder in the general population is estimated to be 1/6,000 from birth and 1/12,000 to 1/14,000 in children under 10 years of age⁸⁷. In the appropriate clinical context, germline testing of TSC1 is recommended.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

GENOMIC FINDINGS

GENE

TP53

ALTERATION

G244D

TRANSCRIPT ID

NM_000546.4

CODING SEQUENCE EFFECT

731G>A

VARIANT CHROMOSOMAL POSITION

chr17:7577550

VARIANT ALLELE FREQUENCY (% VAF)

60.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib⁸⁸⁻⁹¹ or p53 gene therapy such as SGT53⁹²⁻⁹⁶. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype⁹⁷. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer⁹⁸. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer⁹⁹. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone¹⁰⁰. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel¹⁰¹. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck

squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations¹⁰². The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring¹⁰³. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage⁹⁶. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR¹⁰⁴. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)¹⁰⁵.

FREQUENCY & PROGNOSIS

TP53 alterations have been reported in 29-80% of ovarian tumors, with a higher incidence in high-grade pelvic (primary ovarian, tubal, or peritoneal) serous carcinoma, with incidence of 91-97%^{15,106-112}. TP53 alterations have also been reported in serous tubal intraepithelial carcinomas (STICs) of the Fallopian tube, which are suggested to be precursor lesions of tubo-ovarian high grade serous carcinomas¹¹³⁻¹¹⁶. Aberrant p53 expression has been associated with higher ovarian serous carcinoma grade (89-90% of high-grade vs. 6.6-9% of low-grade vs. 0% of benign)¹¹⁷⁻¹¹⁹. In one study, p53 expression was not prognostic in regard to outcome in patients with peritoneum serous carcinoma¹²⁰. TP53 mutations have been reported to be more frequent in advanced stage (63%, 55/87) and higher grade (65%, 42/64) than earlier stage (31%, 14/45) and lower grade (41%, 7/17) ovarian carcinomas¹¹¹. Meta-analysis has suggested that TP53 expression was associated with poorer survival in ovarian epithelial cancers, although the effect was modest and considerable variability was observed between studies¹²¹.

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers¹²². Alterations such as seen here may disrupt TP53 function or expression¹²³⁻¹²⁷.

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2022)¹²⁸. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers¹²⁹⁻¹³¹, including sarcomas¹³²⁻¹³³. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000¹³⁴ to 1:20,000¹³³. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30¹³⁵. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion¹³⁶⁻¹⁴¹. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy¹³⁶⁻¹³⁷. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease¹⁴². Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH^{140,143-144}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

Nab-sirolimus

Assay findings association

TSC1

A186fs*26

AREAS OF THERAPEUTIC USE

Nab-sirolimus is an intravenous nanoparticle albumin-bound mTOR inhibitor that is FDA approved to treat adult patients with advanced or metastatic perivascular epithelioid cell tumors (PEComas). Please see the drug label for full prescribing information.

GENE ASSOCIATION

Based on responses reported for patients with TSC1-altered PEComas⁷³⁻⁷⁴ and epithelial ovarian cancer⁷⁵, TSC1 mutation or loss may predict sensitivity to nab-sirolimus.

SUPPORTING DATA

Nab-sirolimus has been primarily investigated for the treatment of malignant PEComa but is also being explored to treat TSC2- or TSC1-altered solid tumors. The Phase 2 AMPECT trial of nab-sirolimus for patients with

malignant PEComa reported an ORR of 39%, with a significantly higher ORR for patients with TSC2-altered PEComa relative to those lacking TSC2 alterations (89% [8/9] vs. 13% [2/16], $p < 0.001$) and an ORR of 20% (1/5; 1 PR) for patients with TSC1-altered disease⁷³. Patients with TSC1- or TSC2-altered PEComas that had previously progressed on rapalogs have exhibited PRs with nab-sirolimus treatment, including 44% (4/9) of patients with a TSC1/2-altered PEComa in an expanded access program¹⁴⁵ and 1 patient with uterine PEComa⁷⁴. Outside of malignant PEComa, PRs were reported for individual patients with TSC2-altered endometrial stromal sarcoma, leiomyosarcoma, high-grade sarcoma, or lymphangioleiomyomatosis and TSC1-altered epithelial ovarian cancer treated with nab-sirolimus; durable clinical benefit was also reported for a patient with TSC1-altered angiosarcoma treated with nab-sirolimus⁷⁵.

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

CLINICAL TRIALS

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually

updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that

may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or, visit <https://www.foundationmedicine.com/genomic-testing#support-services>.

GENE
TP53
ALTERATION
G244D
RATIONALE

TP53 loss of function alterations may predict sensitivity to WEE1 inhibitors. TP53 missense

mutations may predict sensitivity to therapies that reactivate mutant p53.

NCT04516447
PHASE 1

A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer

TARGETS
WEE1

LOCATIONS: Busan (Korea, Republic of), Seoul (Korea, Republic of), Nedlands (Australia), Sunshine Coast (Australia), South Brisbane (Australia), Melbourne (Australia), Panagyurishte (Bulgaria), Belgrade (Serbia), Tuzla (Bosnia and Herzegovina), Sarajevo (Bosnia and Herzegovina)

NCT03968653
PHASE 1

Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors

TARGETS
WEE1

LOCATIONS: Groningen (Netherlands), Nijmegen (Netherlands), Leiden (Netherlands), Barcelona (Spain)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

CLINICAL TRIALS
GENE
TSC1
ALTERATION

A186fs*26

RATIONALE

Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.

NCT03239015
PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS

EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04337463
PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS

mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04803318
PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS

mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT05125523
PHASE 1

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

TARGETS

mTOR

LOCATIONS: Tianjin (China)

NCT02693535
PHASE 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

TARGETS

ALK, ROS1, AXL, TRKA, MET, TRKC, CDK4, CDK6, FLT3, VEGFRs, CSF1R, KIT, RET, mTOR, ERBB2, MEK, BRAF, PARP, PD-1, CTLA-4, EGFR, ERBB4

LOCATIONS: Hawaii, Washington, Oregon, California

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

CLINICAL TRIALS
NCT03297606
PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS

VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)

NCT04185831
PHASE 2

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

TARGETS

PD-L1, MEK, mTOR

LOCATIONS: Uppsala (Sweden), Gothenburg (Sweden)

NCT01582191
PHASE 1

A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer

TARGETS

mTOR, EGFR, SRC, RET, VEGFRs

LOCATIONS: Texas

NCT03203525
PHASE 1

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

TARGETS

VEGFA, mTOR

LOCATIONS: Texas

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

AR
S495N

CIC
P603S

MLL2
A2925V and
Q3745_H3746insQ

MSH2
H839R

POLE
R150Q

SMARCA4
amplification

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

APPENDIX
Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B or WTX)	
APC	AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX
AURKA	AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2
BCL6	BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1
BTG2	BTK	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73	CDH1
CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B	CDKN2C
CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R	CTCF
CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1	DDR2
DIS3	DNMT3A	DOT1L	EED	EGFR	EMSY (C11orf30)	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12	FGF14
FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3	FGFR4
FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3	GATA4
GATA6	GID4 (C17orf39)	GNA11	GNA13	GNAS	GNAS	GRM3	GSK3B	H3-3A (H3F3A)
HDAC1	HGF	HNFA1	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11 (MRE11A)	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD2 (WHSC1 or MMSET)	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	NTRK3
P2RY8	PALB2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)
PDGFRA	PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1
PMS2	POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI
PRKN (PARK2)	PTCH1	PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51
RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10
REL	RET	RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO
SNCAIP	SOC1	SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3
STK11	SUFU	SYK	TBX3	TEK	TENT5C (FAM46C)	TET2	TET2	TGFB2
TIPARP	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2	TYRO3	U2AF1	VEGFA
VHL	WT1	XPO1	XRCC2	ZNF217	ZNF703			

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC*	TERT**	TPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS


Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # ORD-1479454-01

APPENDIX

About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a., Ciplstraat 3, 2440 Geel, Belgium. 

ABOUT FOUNDATIONONE CDx

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details:
www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLE

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes

detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture-selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g., gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for *ERBB2* and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical

methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fraction-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

APPENDIX

About FoundationOne®CDx

- analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.
- TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
 - Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score $\geq 16\%$ will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
 - The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and

extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.

- Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
- Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
- Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in <https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/> report the frequency of *HER2* overexpression as 20% in breast cancer. Based on the F1CDx *HER2* CDx concordance study, approximately 10% of *HER2* amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal

hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

*Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*, *RAD51C*, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 26 October 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1479454-01

APPENDIX

About FoundationOne®CDx

tumor sequencing is germline or somatic.
Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1*, *CBL*, *DNMT3A*, *IDH2*, *JAK2*, *KMT2D (MLL2)*, *MPL*, *MYD88*, *SF3B1*, *TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking

into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
mut/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7:3.0

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of the data. The median exon coverage for this sample is 894x. The suitability of use.

ORDERED TEST # **ORD-1479454-01**
APPENDIX
References

1. Coleman RL, et al. *Lancet* (2017) PMID: 28916367
2. Swisher EM, et al. *Lancet Oncol.* (2017) PMID: 27908594
3. Mirza MR, et al. *N. Engl. J. Med.* (2016) PMID: 27717299
4. Telli ML, et al. *Clin. Cancer Res.* (2016) PMID: 26957554
5. Timms KM, et al. *Breast Cancer Res.* (2014) PMID: 25475740
6. Wang ZC, et al. *Clin. Cancer Res.* (2012) PMID: 22912389
7. Telli ML, et al. *J. Clin. Oncol.* (2015) PMID: 25847929
8. Isakoff SJ, et al. *J. Clin. Oncol.* (2015) PMID: 25847936
9. Elvin et al., 2017; ASCO Abstract 5512
10. Abkevich V, et al. *Br. J. Cancer* (2012) PMID: 23047548
11. Marquard AM, et al. *Biomark Res* (2015) PMID: 26015868
12. Pedersen BS, et al. *Genes Chromosomes Cancer* (2013) PMID: 23716468
13. Watkins JA, et al. *Breast Cancer Res.* (2014) PMID: 25093514
14. Vanderstichele A, et al. *Eur. J. Cancer* (2017) PMID: 28950147
15. *Nature* (2011) PMID: 21720365
16. *N. Engl. J. Med.* (2003) PMID: 12736286
17. Gatalica Z, et al. *Cancer Epidemiol. Biomarkers Prev.* (2014) PMID: 25392179
18. Kroemer G, et al. *Oncoimmunology* (2015) PMID: 26140250
19. Lal N, et al. *Oncoimmunology* (2015) PMID: 25949894
20. Le DT, et al. *N. Engl. J. Med.* (2015) PMID: 26028255
21. Ayers et al., 2016; ASCO-SITC Abstract P60
22. Segev Y, et al. *Eur. J. Gynaecol. Oncol.* (2015) PMID: 26775351
23. Plisiecka-Hałasa J, et al. *Anticancer Res. ()* PMID: 18507046
24. Huang HN, et al. *Histopathology* (2015) PMID: 25195947
25. Strickland et al., 2016; ASCO Abstract 5514
26. Aysal A, et al. *Am. J. Surg. Pathol.* (2012) PMID: 22189970
27. Kocarnik JM, et al. *Gastroenterol Rep (Oxf)* (2015) PMID: 26337942
28. You JF, et al. *Br. J. Cancer* (2010) PMID: 21081928
29. Bairwa NK, et al. *Methods Mol. Biol.* (2014) PMID: 24623249
30. Boland CR, et al. *Cancer Res.* (1998) PMID: 9823339
31. Pawlik TM, et al. *Dis. Markers* (2004) PMID: 15528785
32. Boland CR, et al. *Gastroenterology* (2010) PMID: 20420947
33. Samstein RM, et al. *Nat. Genet.* (2019) PMID: 30643254
34. Goodman AM, et al. *Mol. Cancer Ther.* (2017) PMID: 28835386
35. Goodman AM, et al. *Cancer Immunol Res* (2019) PMID: 31405947
36. Cristescu R, et al. *Science* (2018) PMID: 30309915
37. Ready N, et al. *J. Clin. Oncol.* (2019) PMID: 30785829
38. Hellmann MD, et al. *N. Engl. J. Med.* (2018) PMID: 29658845
39. Hellmann MD, et al. *Cancer Cell* (2018) PMID: 29657128
40. Hellmann MD, et al. *Cancer Cell* (2018) PMID: 29731394
41. Rozeman EA, et al. *Nat Med* (2021) PMID: 33558721
42. Sharma P, et al. *Cancer Cell* (2020) PMID: 32916128
43. Marabelle A, et al. *Lancet Oncol.* (2020) PMID: 32919526
44. Ott PA, et al. *J. Clin. Oncol.* (2019) PMID: 30557521
45. Cristescu R, et al. *J Immunother Cancer* (2022) PMID: 35101941
46. Friedman CF, et al. *Cancer Discov* (2022) PMID: 34876409
47. Sturgill EG, et al. *Oncologist* (2022) PMID: 35274716
48. Schenker et al., 2022; AACR Abstract 7845
49. Legrand et al., 2018; ASCO Abstract 12000
50. Chalmers ZR, et al. *Genome Med* (2017) PMID: 28420421
51. Strickland KC, et al. *Oncotarget* (2016) PMID: 26871470
52. Pfeifer GP, et al. *Mutat. Res.* (2005) PMID: 15748635
53. Hill VK, et al. *Annu Rev Genomics Hum Genet* (2013) PMID: 23875803
54. Pfeifer GP, et al. *Oncogene* (2002) PMID: 12379884
55. Rizvi NA, et al. *Science* (2015) PMID: 25765070
56. Johnson BE, et al. *Science* (2014) PMID: 24336570
57. Choi S, et al. *Neuro-oncology* (2018) PMID: 29452419
58. Cancer Genome Atlas Research Network, et al. *Nature* (2013) PMID: 23636398
59. Briggs S, et al. *J. Pathol.* (2013) PMID: 23447401
60. Heitzer E, et al. *Curr. Opin. Genet. Dev.* (2014) PMID: 24583393
61. *Nature* (2012) PMID: 22810696
62. Roberts SA, et al. *Nat. Rev. Cancer* (2014) PMID: 2568919
63. Tee AR, et al. *Curr. Biol.* (2003) PMID: 12906785
64. Mallela K, et al. *Mol Cell Biochem* (2021) PMID: 33575875
65. Adib E, et al. *Clin Cancer Res* (2021) PMID: 33727259
66. Nassar AH, et al. *Mol Cancer Ther* (2020) PMID: 31653662
67. Voss MH, et al. *Clin. Cancer Res.* (2018) PMID: 30327302
68. Ali SM, et al. *Eur. Urol.* (2015) PMID: 25796537
69. Lim SM, et al. *Oncotarget* (2016) PMID: 26859683
70. Kwiatkowski DJ, et al. *Clin. Cancer Res.* (2016) PMID: 26831717
71. Hamieh L, et al. *PLoS Genet* (2018) PMID: 30256787
72. Roldan-Romero JM, et al. *Int J Cancer* (2020) PMID: 31335987
73. Wagner AJ, et al. *J Clin Oncol* (2021) PMID: 34637337
74. Koppa P, et al. *Cureus* (2021) PMID: 34123648
75. Dickson et al., 2021; ASCO Abstract 3111
76. Knowles MA, et al. *Biochem. Soc. Trans.* (2003) PMID: 12773163
77. Cliby W, et al. *Cancer Res.* (1993) PMID: 8485726
78. Devlin J, et al. *Br. J. Cancer* (1996) PMID: 8595153
79. Schultz DC, et al. *Cancer Res.* (1995) PMID: 7743516
80. Inoki K, et al. *Genes Dev.* (2003) PMID: 12869586
81. Milloza A, et al. *Hum. Mol. Genet.* (2000) PMID: 10915759
82. Hoogeveen-Westerveld M, et al. *Biochim. Biophys. Acta* (2010) PMID: 20547222
83. Hodges AK, et al. *Hum. Mol. Genet.* (2001) PMID: 11741833
84. Ann. N. Y. Acad. Sci. (1991) PMID: 2039135
85. van Slegtenhorst M, et al. *Science* (1997) PMID: 9242607
86. Crino PB, et al. *N. Engl. J. Med.* (2006) PMID: 17005952
87. Curatolo P, et al. *Lancet* (2008) PMID: 18722871
88. Hirai H, et al. *Cancer Biol. Ther.* (2010) PMID: 20107315
89. Bridges KA, et al. *Clin. Cancer Res.* (2011) PMID: 21799033
90. Rajeshkumar NV, et al. *Clin. Cancer Res.* (2011) PMID: 21389100
91. Osman AA, et al. *Mol. Cancer Ther.* (2015) PMID: 25504633
92. Xu L, et al. *Mol. Cancer Ther.* (2002) PMID: 12489850
93. Xu L, et al. *Mol. Med.* (2001) PMID: 11713371
94. Camp ER, et al. *Cancer Gene Ther.* (2013) PMID: 23470564
95. Kim SS, et al. *Nanomedicine* (2015) PMID: 25240597
96. Pirolo KF, et al. *Mol. Ther.* (2016) PMID: 27357628
97. Leijen S, et al. *J. Clin. Oncol.* (2016) PMID: 27601554
98. Moore et al., 2019; ASCO Abstract 5513
99. Leijen S, et al. *J. Clin. Oncol.* (2016) PMID: 27998224
100. Oza et al., 2015; ASCO Abstract 5506
101. Lee J, et al. *Cancer Discov* (2019) PMID: 31315834
102. Méndez E, et al. *Clin. Cancer Res.* (2018) PMID: 29535125
103. Seligmann JF, et al. *J Clin Oncol* (2021) PMID: 34538072
104. Gourley et al., 2016; ASCO Abstract 5571
105. Park H, et al. *ESMO Open* (2022) PMID: 36084396
106. Ahmed AA, et al. *J. Pathol.* (2010) PMID: 20229506
107. Wojnarowicz PM, et al. *PLoS ONE* (2012) PMID: 23029043
108. Kuhn E, et al. *J. Pathol.* (2012) PMID: 21990067
109. Karst AM, et al. *J Oncol* (2010) PMID: 19746182
110. Gadducci A, et al. *Gynecol. Endocrinol.* (2012) PMID: 22304686
111. Rechsteiner M, et al. *Exp. Mol. Pathol.* (2013) PMID: 23965232
112. Okamoto A, et al. *Cancer Res.* (1991) PMID: 1680546
113. McDaniel AS, et al. *JAMA Oncol* (2015) PMID: 26181193
114. Kindelberger DW, et al. *Am. J. Surg. Pathol.* (2007) PMID: 17255760
115. Meserve EEK, et al. *Mod. Pathol.* (2017) PMID: 28106106
116. Kurman RJ, et al. *Hum. Pathol.* (2011) PMID: 21683865
117. Altman AD, et al. *Mod. Pathol.* (2013) PMID: 23558569
118. Giurgea LN, et al. *Rom J Morphol Embryol* (2012) PMID: 23303200
119. Rajesh NG, et al. *Indian J Pathol Microbiol* (2007) PMID: 17883046
120. Lee S, et al. *Int. J. Gynecol. Pathol.* (2013) PMID: 24071870
121. de Graeff P, et al. *Br. J. Cancer* (2009) PMID: 19513073
122. Brown CJ, et al. *Nat. Rev. Cancer* (2009) PMID: 19935675
123. Joerger AC, et al. *Annu. Rev. Biochem.* (2008) PMID: 18410249
124. Kato S, et al. *Proc. Natl. Acad. Sci. U.S.A.* (2003) PMID: 12826609
125. Kamada R, et al. *J. Biol. Chem.* (2011) PMID: 20978130
126. Zerdoumi Y, et al. *Hum. Mol. Genet.* (2017) PMID: 28472496
127. Yamada H, et al. *Carcinogenesis* (2007) PMID: 17690113
128. Landrum MJ, et al. *Nucleic Acids Res.* (2018) PMID: 29165669
129. Bougeard G, et al. *J. Clin. Oncol.* (2015) PMID: 26014290
130. Sorrell AD, et al. *Mol Diagn Ther* (2013) PMID: 23355100
131. Nichols KE, et al. *Cancer Epidemiol. Biomarkers Prev.* (2001) PMID: 11219776
132. Kleihues P, et al. *Am. J. Pathol.* (1997) PMID: 9006316
133. Gonzalez KD, et al. *J. Clin. Oncol.* (2009) PMID: 19204208
134. Lalloo F, et al. *Lancet* (2003) PMID: 12672316
135. Mandelker D, et al. *Ann. Oncol.* (2019) PMID: 31050713
136. Jaiswal S, et al. *N. Engl. J. Med.* (2014) PMID: 25426837
137. Genovese G, et al. *N. Engl. J. Med.* (2014) PMID: 25426838
138. Xie M, et al. *Nat. Med.* (2014) PMID: 25326804
139. Acuna-Hidalgo R, et al. *Am. J. Hum. Genet.* (2017) PMID: 28669404
140. Severson EA, et al. *Blood* (2018) PMID: 29678827
141. Fuster JJ, et al. *Circ. Res.* (2018) PMID: 29420212
142. Hematology Am Soc Hematol Educ Program (2018) PMID: 30504320
143. Chabon JJ, et al. *Nature* (2020) PMID: 32269342
144. Razavi P, et al. *Nat. Med.* (2019) PMID: 31768066
145. Dickson et al., 2021; CTOS Abstract 1818755

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.